2103-86-8

Basic information

• Product Name: Thiazole, 2-(methylthio)-4-phenyl-
• CAS NO: 2103-86-8
• Molecular Formula: C10H9NS2
• Molecular Weight: 207.32
• Mol File: 2103-86-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Thiazole, 2-(methylthio)-4-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Thiazole, 2-(methylthio)-4-phenyl-(2103-86-8)
• EPA Substance Registry System: Thiazole, 2-(methylthio)-4-phenyl-(2103-86-8)

Safety Data

• Hazardous Substances Data: 2103-86-8(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 23349-44-2 bis(4-phenylthiazol-2-yl) disulfide 
• 1826-12-6 4-phenyl-thiazole 
• 5053-24-7 2-methylthio-1,3-thiazole 
• 615-22-5 2-methylmercaptobenzothiazole 
• 2103-88-0 4-phenylthiazole-2(3H)-thione 
• 2103-88-0 2-Mercapto-4-phenylthiazole 
• 74-88-4 methyl iodide 
• 74-93-1 methylthiol 
• 83893-97-4 (thiocyanatoethynyl)benzene 
• 16696-83-6 S-methyl dithiocarbamate 
• 70-11-1 α-bromoacetophenone 

Downstream Products

• 615-22-5 2-methylmercaptobenzothiazole 
• 1826-12-6 4-phenyl-thiazole 
• 5053-24-7 2-methylthio-1,3-thiazole 
• 56657-77-3 2-methanesulfinyl-4-phenyl-thiazole 
• 21402-19-7 3-methyl-4-phenylthiazole-2(3H)-thione 

Relevant articles and documents

Cycloaddition reactions of thiazolium azomethine ylides: Application to pyrrolo[2,1-b]thiazoles

Thiazolium azomethine ylides, equipped with a C-2 methanethiol group, participate in an efficient [3 + 2] cycloaddition reaction with acetylene derivatives to yield unique pyrrolo[2,1-b]thiazoles. The elimination of the methanethiol leaving group from the cycloadduct has replaced the need for a separate oxidation step and suppresses ring-opening side reactions. Products were obtained in short synthetic sequences to demonstrate their use as a scaffold for compound libraries.

2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE

The present invention pertains to certain 2-[3H-thiazol-2-ylidinemethyl]pyridine compounds and analogs thereof, which, inter alia, inhibit cell proliferation, treat cancer, etc., and more specifically to compounds of the following formula, wherein RA1, RA2, RA3, RA4, RB1, RB2, RNA, RNB, and X? are as defined herein: The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cell proliferation, and in the treatment of proliferative conditions such as cancer, etc.